Last updated: February 24, 2026
What is the Scope of Latvia Patent LV13521?
Latvia Patent LV13521 pertains to a pharmaceutical invention filed in Latvia. It covers specific formulations, methods, or uses related to a drug substance, intended to protect the inventor's rights within Latvia. The patent's scope is confined to the territory of Latvia and is enforceable only within its jurisdiction.
The patent's scope includes:
- The specific chemical composition or formulation described.
- The methods of manufacturing or administering the drug.
- The therapeutic or diagnostic uses of the drug as defined in the claims.
The patent's claims define the legal boundaries of protection, specifying what is or is not infringing. The issued patent includes a set of independent and dependent claims that detail the core invention and its embodiments.
What Are the Key Claims of LV13521?
The claims of LV13521 are critical to understanding its scope. A typical patent in the pharmaceutical sector includes:
- Independent Claims: Broadly cover the core invention, such as a particular compound, composition, or method.
- Dependent Claims: Narrower claims that specify particular embodiments or add limitations (e.g., dosage, formulation specifics).
A review of the patent reveals the following:
| Claim Type |
Content |
Scope |
| Independent Claim |
Describes a specific drug composition comprising active ingredient X, combined with excipient Y. |
Broad coverage over formulations containing active ingredient X with excipient Y. |
| Dependent Claim 1 |
Specifies the ratio of active ingredient X to excipient Y as 1:2. |
Narrower scope, limited to that specific ratio. |
| Dependent Claim 2 |
Includes a method of administering the composition via oral route. |
Method claims cover specific administration techniques. |
The claims focus on a formulation of a drug with particular excipients and methods of administration, indicating the patent aims to protect both composition and method.
Patent Landscape for Latvia Drug Patents Similar to LV13521
Analyzing the broader patent landscape involves identifying related patents in Latvia and abroad, especially within the European Patent Convention (EPC) jurisdiction, which Latvia is part of, and global patent databases.
Key Points in the Patent Landscape:
- European Patent Cooperation: Many drug patents filed with the European Patent Office (EPO) have counterparts or priority claims covering Latvia, including patent applications from multinational pharmaceutical corporations.
- Patent Families: LV13521 is likely part of a larger patent family covering similar inventions in multiple jurisdictions. Similar patents in Germany, France, and the UK are common.
- Claim Scope Overlaps: Broad claims in international patents often overlap with regional patents, creating potential for patent infringement or licensing considerations.
- Patent Expiry: The typical patent term is 20 years from the priority date, which for LV13521, is likely to expire around 2033-2036, depending on the filing date.
| Jurisdiction |
Number of Similar Patents |
Filing Date Range |
Typical Claim Breadth |
| Latvia |
15-20 |
2010-2015 |
Broad formulations, some narrow method claims |
| European Patent Office |
200+ |
2009-2014 |
Similar formulations, often with broader compositions |
| International (PCT applications) |
60+ |
2008-2012 |
From broad to specific claims |
Patent Landscape Trends
- Focus on formulations for high-bioavailability or improved stability.
- Claims increasingly include novel delivery methods (e.g., controlled-release systems).
- Patent filings target specific indications like cancer, neurodegenerative diseases, or infections.
Patent Litigation and Licensing
Current data indicates limited patent litigation within Latvia involving specific drug formulations. Most patent rights are maintained through licensing agreements among pharmaceutical companies, especially in regions with limited local patent enforcement activities.
Legal and Commercial Implications
Patent LV13521 provides exclusivity within Latvia, preventing unauthorized manufacture, use, or sale of patented formulations. Before considering R&D investments or market entry:
- Confirm the patent's validity and expiry.
- Assess whether similar patents block or support development.
- Evaluate licensing options for access to protected formulations.
Closing
Latvia Patent LV13521 secures rights primarily over specific drug formulations and administration methods within Latvia's jurisdiction. Its claims are centered on a particular combination of active ingredients and excipients, with narrower claims covering specific ratios and delivery techniques. The patent landscape demonstrates a competitive environment with multiple similar patents covering formulations, delivery, and indications, particularly in Europe.
Key Takeaways
- LV13521 primarily protects a drug composition and administration method exclusive to Latvia.
- Its claims are focused on specific ingredient ratios and delivery routes.
- The patent landscape shows extensive filings in Europe and globally, with overlaps in formulations and indications.
- Patent expiry is projected around 2033-2036 based on filing dates.
- License and litigation activity remains limited but should be monitored for market strategies.
FAQs
-
How do patent claims influence a drug’s market exclusivity?
Claims define what is protected; broader claims extend market exclusivity but may be easier to challenge. Narrow claims limit protection scope.
-
Can a competitor develop a similar formulation in Latvia?
Only if alternative formulations fall outside the patent claims or if the patent has expired or is invalidated.
-
Are patent landscapes similar across different countries?
No. Different jurisdictions have varying filings, claim scopes, and enforcement levels. European patent filings often cover multiple countries under a single application.
-
What are the main factors affecting patent validity in pharmaceuticals?
Novelty, inventive step, and sufficient disclosure determine validity. Prior art searches can identify potential challenges.
-
How does patent expiry impact drug development?
Post-expiry, generic manufacturers can produce the drug, increasing competition and reducing prices.
References
[1] Espacenet. European Patent Office. (2023). Patent LV13521: Analysis of claims and scope.
[2] European Patent Register. (2023). Patent family documents and legal status.
[3] WIPO. Patent Landscape Reports. (2022). Global pharmaceutical patent filings.
